Originally published In Press as doi:10.1074/jbc.M206801200 on August 6, 2002
J. Biol. Chem., Vol. 277, Issue 43, 40989-40996, October 25, 2002
2 Adrenergic Receptor Activation
MODULATION OF THE PROLINE KINK IN TRANSMEMBRANE 6 BY A ROTAMER
TOGGLE SWITCH*
Lei
Shi
§¶,
George
Liapakis¶
,
Rui
Xu§,
Frank
Guarnieri**,
Juan A.
Ballesteros
, and
Jonathan A.
Javitch
§§§¶¶
From the
Center for Molecular Recognition,
Departments of § Pharmacology and
§§ Psychiatry, Columbia University College of
Physicians and Surgeons, New York, New York 10032, the
** Sarnoff Corporation, Princeton, New Jersey 08543, 
Novasite Pharmaceuticals Inc., San Diego,
California 92121, and the
Department of Pharmacology, University
of Crete School of Medicine, Heraklion 71110, Greece
Received for publication, July 8, 2002, and in revised form, August 2, 2002
 |
ABSTRACT |
In many rhodopsin-like G-protein-coupled
receptors, agonist binding to a cluster of aromatic residues in TM6 may
promote receptor activation by altering the configuration of the TM6
Pro-kink and by the subsequent movement of the cytoplasmic end of TM6
away from TM3. We hypothesized that the highly conserved
Cys6.47, in the vicinity of the conserved
Pro6.50, modulates the configuration of the aromatic
cluster and the TM6 Pro-kink through specific interactions in its
different rotamer configurations. In the
2 adrenergic
receptor, mutation of Cys6.47 to Thr, which in an
-helix
has a different rotamer distribution from Cys and Ser, produced a
constitutively active receptor, whereas the Ser mutant was similar to
wild-type receptor. Use of the biased Monte Carlo technique of
Conformational Memories showed that the rotamer changes among
Cys/Ser/Thr6.47, Trp6.48, and
Phe6.52 are highly correlated, representing a rotamer
"toggle switch" that may modulate the TM6 Pro-kink. Differential
modulation of the accessibility of Cys6.47 and an
engineered Cys6.52 in wild type and a constitutively active
background provides experimental support for the association of this
rotamer switch with receptor activation.
 |
INTRODUCTION |
G-protein-coupled receptors
(GPCRs)1 are comprised of an
extracellular N terminus, seven transmembrane
-helical segments
(TMs) connected by intracellular and extracellular loops, and a
cytoplasmic C terminus. In the
2 adrenergic receptor
(
2AR) and related rhodopsin-like GPCRs that bind small
molecules, the binding site is formed among their seven TMs in a
water-accessible binding site crevice (1). The transmembrane domain of
these receptors, therefore, transduces the binding of ligands, such as
biogenic amines, to the activation of intracellular G-proteins, which
in turn mediate downstream signal transduction pathways. Even in
peptide and glycoprotein hormone receptors, in which the binding site
is formed, at least in part, by extracellular loops or by large
N-terminal domains, respectively, agonist binding must still be
transduced via the transmembrane segments to the intracellular
G-protein-interacting regions of these receptors.
Understanding the function of GPCRs at a molecular level requires an
understanding of how agonist binding to the receptor is converted into
receptor activation (2). Studies based on electron paramagnetic
resonance spectroscopy, fluorescence spectroscopy, alterations in
cysteine accessibility, and engineering of metal-binding sites have
altogether pointed to a key role for conformational changes of TM3 and
TM6 in receptor activation (3-8). It has been suggested that
protonation of the Asp in the highly conserved (D/E)RY motif at
the cytoplasmic side of TM3 leads to release of constraining
intramolecular interactions, thereby resulting in movements of TM3 and
TM6 and conversion of the receptor to the active state. This hypothesis
has been supported by the observation that charge-neutralizing
mutations of the Asp/Glu3.49 in TM3 lead to increased
agonist-independent activation of a number of GPCRs (7, 9-12).
Experiments using cysteine cross-linking and engineered metal
ion-binding sites (3, 4, 13) suggest that residues at the cytoplasmic
ends of TM3 and TM6 face each other. We proposed that in the inactive
state Arg3.50, in addition to interacting with
Asp3.49, also interacts with the conserved
Glu6.30 at the cytoplasmic end of TM6, and that this
interaction contributes to maintaining the receptor in the inactive
state by holding together the cytoplasmic ends of TM3 and TM6. Our
experimental data (14) together with the high-resolution structure of
rhodopsin (15) suggest that ionic interactions between
Asp/Glu3.49, Arg3.50, and Glu6.30
may constitute a common switch governing the activation of many rhodopsin-like receptors. Disruption of the interaction between TM3 and
TM6 produces constitutive receptor activation and the extent of
constitutive activation is highly correlated with the extent of
conformational rearrangement in TM6 (14).
Experimental and computational simulation studies indicate that
conformational switches in transmembrane
-helices can be generated
via Pro-containing motifs that form flexible molecular hinges (16).
Although Farrens et al. (3) predicted that a rigid body
motion of TM6 relative to TM3 was associated with the activation of
rhodopsin, the movements crucial to activation may involve flexibility
about the hinge formed by the highly conserved Pro in TM6
(Pro-2886.50 in
2AR) (17). In rhodopsin, and
presumably in the
2AR, TM6 exists in a highly bent
configuration, with its cytoplasmic end near to the cytoplasmic end of
TM3 (15).
In the
2AR and related aminergic receptors, a cluster of
highly conserved aromatic residues surrounding the Pro-kink, including Phe6.44, Trp6.48, Phe6.51, and
Phe6.52 in catecholamine receptors, face the binding-site
crevice (reviewed in Ref. 1). Binding of agonist to a residue or
residues in this "aromatic cluster" has been hypothesized to induce
or stabilize an altered configuration of the side chains within this
cluster that promotes receptor activation (17). Such a conformational rearrangement of the aromatic cluster may be associated with an alteration in the configuration of the TM6 Pro-kink and the subsequent movement of the cytoplasmic end of TM6 away from TM3.
In the
2AR the conserved endogenous
Cys-2856.47, positioned i-3 from the conserved
Pro-2886.50, becomes accessible to methanethiosulfonate
ethylammonium (MTSEA) in the binding-site crevice in constitutively
active mutants (CAMs) (6, 7, 14). Cys, Ser, and Thr can hydrogen bond
(H-bond) to the backbone in an
-helix, and this interaction may
impact significantly not only the local conformation but may also lead to long range conformational changes through bends and distortions generated in the helix backbone (18-20). The highly conserved
Cys-2856.47 near the Pro-kink at 6.50 can H-bond to
different backbone carbonyls in different rotamer positions, and its
rotamer position may modulate the TM6 kink.
We hypothesized that the configuration of the TM6 Pro-kink in a GPCR
would be correlated with constitutive activity and that both
Cys6.47 and the aromatic cluster may impact this
configuration. We tested these hypotheses in the
2AR by
assessing the binding and activation properties of Cys6.47
mutants. The biased Monte Carlo technique of Conformational Memories was used to probe for correlations between the Cys-2856.47
rotamer position, the configuration of the aromatic cluster in TM6, and
the TM6 Pro-kink conformation. We carried out cysteine accessibility
experiments to test a prediction that arose from the simulations, and
the experimental results supported the existence of a critical rotamer
"toggle switch" (17) associated with receptor activation.
 |
EXPERIMENTAL PROCEDURES |
Numbering of Residue and Residue Index
Residues are numbered according to their positions in the human
2AR sequence. We also index residues relative to the
most conserved residue in the TM in which it is located (21). By definition, the most conserved residue is assigned the position index
"50," e.g. Pro-2886.50 and therefore
Leu-2876.49 and Phe-2896.51. This indexing
simplifies the identification of aligned residues in different GPCRs.
Mutants are named as WT residue, residue number, superscript index
number, and mutant residue where the residues are given in single
letter codes.
Nomenclature of
1 Rotamer
Different nomenclatures have been used to describe the rotamers
of side chain torsion angles. When the heavy atom at the
position
is at a position opposite to the backbone nitrogen, when viewed from
-carbon to
-carbon, we define the
1 rotamer as in the
trans (t) position; from the same viewing angle,
when the heavy atom at the
position is at a position opposite to
the backbone carbon, we define the
1 rotamer as in the
gauche+ (g+) position; when the
-carbon is
opposite to the
-hydrogen, we define the
1 rotamer as in the
gauche
(g
) position.
2-Plasmids and Site-directed Mutagenesis
The mutations were generated by the polymerase chain
reaction-mediated mutagenesis using Pfu polymerase (Stratagene). The polymerase chain reaction-generated DNA fragments containing the mutations were subcloned into the appropriate plasmid. The mutations were identified initially through the presence of diagnostic
restriction sites introduced via the mutated oligonucleotides and
subsequently verified by DNA sequencing analysis of the polymerase
chain reaction-generated segments. For stable expression in HEK 293 cells, this cDNA was subcloned into the bicistronic expression
vector pCIN4-SF
2AR6His (22).
Cell Culture and Transfection
HEK 293 cells were maintained at 37 °C in 5% CO2
in Dulbecco's modified Eagle's medium/F-12 (1:1) containing 3.15 g/liter of glucose in 10% bovine calf serum. The HEK 293 cells were
transfected with 2 µg of the pCIN4 constructs using the
LipofectAMINE/Opti-MEM (Invitrogen) transfection system, and a
stably transfected pool was selected with Geneticin (700 µg/ml)
(6).
Membrane Preparation and [3H]CGP-12177 Binding
To increase the expression of the constitutively active mutant,
a 10 µM concentration of the inverse agonist sotalol was
added to the growth medium of HEK 293 cells stably expressing WT or mutant
2AR for 1-2 days. Membranes were prepared as
described previously (14). Aliquots of diluted membrane suspension (200 µl) were incubated in binding buffer either with six different concentrations of the antagonist [3H]CGP-12177 between 40 and 1100 pM (in saturation binding experiments) or with
increasing concentrations of agonists or antagonists in the presence of
100 pM [3H]CGP-12177 (in competition binding
experiments). The total volume was adjusted to 1.0 ml, and the binding
experiments and data analysis were performed as described previously
(22, 23).
cAMP Accumulation Assay
HEK 293 cells stably expressing the WT
2AR or the
mutants were plated in 96-well cell culture plates (pretreated with
poly-L-lysine, 0.1 mg/ml) at a density of 40,000-60,000
cells/well. After incubation overnight at 37 °C in 5%
CO2, the cells were 95-100% confluent. The medium was
removed, and 100 µl of 0-60 µM
N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) in
Opti-MEM (Invitrogen) was added to normalize the concentration of
receptor (22). The concentration of EEDQ used for a particular experiment was adjusted based on the level of cell surface expression of the particular mutant, as higher expressing receptors such as WT
required higher concentrations of EEDQ for appropriate normalization. The level of cell surface expression of WT and the mutants was determined by specific binding of the hydrophilic radioligand [3H]CGP-12177 at a concentration 10-fold higher than its
KD (0.9 nM). cAMP accumulation assay was
performed as described previously (22).
Reactions of F2906.52C Mutants with MTS Reagents
Whole cells from a 35-mm dish were resuspended in 400 µl of
buffer A. Aliquots (50 µl) of cell suspension were incubated with freshly prepared MTSEA (Toronto Research Biochemicals) at the stated
concentrations at room temperature for 2 min. Cell suspensions were
then diluted 20-fold, and 300-µl aliquots were used to assay for
[3H]CGP-12177 (1.2 nM) binding in triplicate
as described above. The fractional inhibition was calculated as
1-[(specific binding after MTS reagent)/(specific binding without
reagent)].
Rotamer Statistics of Cys/Ser/Thr of
Membrane Proteins
The distributions of the
1 rotamer of Cys/Ser/Thr were
calculated from all the high resolution (
3 Å) membrane protein
structures currently available. The structures were downloaded from the
Protein Data Bank. The list and definitions of transmembrane
-helical segments were updated and modified using the Membrane
Protein Topology data base (24). Cys/Ser/Thr in transmembrane
-helical segments were only included if at least 5 residues
N-terminal to the identified position were within the
-helix. Only
regions with a B-value
40 (25) and structures with a resolution
3 Å were included in the analysis. Our rationale was that a resolution
3 Å can differentiate whether or not a region is
-helical and B-values
40 of the Cys/Ser/Thr side chain atoms ensure that
coordinate information was reliable.
Conformational Memories
The approach of Conformational Memories, which is a two-phase
biased Monte Carlo simulation, was described previously (26). We used
this algorithm, which was implemented in CHARMM (27), to probe the
conformational space of TM6 of human
2AR.
Initial Structures--
The template was TM6 (6.40-6.56) of
chain A of the bovine rhodopsin structure (Protein Data Bank number
1HZX). The side chains of the residues were mutated to those of
the aligned positions in the human
2AR. Four Ala
residues in a standard
-helical conformation were added at the N and
C termini. Thus, there are totally 25 residues in the system. The
-helix was capped by acetamide at the N terminus and
N-methylamide at the C terminus.
1 of 6.47 (Cys/Ser/Thr) was manually placed in gauche+
(g+), gauche
(g
), or
trans (t).
1 of 6.48 and 6.52 were manually
placed in g+ or t, and in
g+/g+, g+/t, and
t/t combinations (see "Results"). The initial
structures were energy minimized by CHARMM (27b1). During the
minimization, the backbone atoms were harmonically constrained with a
force constant of 10, and the
1 of the 6.47, 6.48, and 6.52 side
chains were constrained by well shaped energy barriers around a
specific rotamer.
Biased (Constrained) Exploring Phase--
In the initial
conformational memories, the backbone angles (
and
) of
6.44-6.52 were distributed with ±50° freedom from the rhodopsin
structure values (10% in each of the designated 10° buckets); those
of 6.40-6.43 and 6.53-6.56 were distributed within ±25° freedom
(20% at each of designated 10° buckets). The dihedral angles of the
alanines in the N and C termini were set to those of a standard
-helix (
=
65°
=
40°). Side chain torsion
angles were able to freely rotate except for the
1 of 6.47. The
1
of 6.47 (Cys/Ser/Thr) was constrained to g+, g
, or t as specified under "Results."
Forty runs of Monte Carlo simulated annealing were carried out
within the above defined conformational memories, with a distance dependent dielectric with a coefficient of 2. Each run of Monte Carlo
simulated annealing consisted of a walk from 2070 to 310 K in 18 temperature intervals with a cooling schedule of
Tn+1 = 0.9 Tn, and
25,000 steps per temperature. At each step, 2 dihedral angles were
randomly selected to change within the allowed conformational memories,
and the trial conformation was accepted or rejected according to the
standard Metropolis criteria with a Boltzmann probability function
defined at the given temperature.
Biased Sampling Phase--
Several hundred structures were
collected for each combination of
1 of 6.47, 6.48, and 6.52 (see
"Results"), based on the biased conformational memories created by
the biased (constrained) exploration phase. Each structure was
generated after a run of biased Monte Carlo simulated annealing. Each
run in this phase consisted of a walk of 15,000 steps at 310 K. At each
step, 2 dihedral angles were randomly selected to change within the
output conformational memories from the biased exploring phase.
Difference structures were generated by changing the odd random number seed.
Analysis of the Output Simulation Structures
The resulting simulation structures were first classified
according to their
1 rotamer positions of 6.48 and 6.52 (see
"Results"). For each structure in each group, the corresponding
coordinates were extracted to calculate the following parameters: the
and
of 6.44-6.52 and their individual averages for each group;
the population distribution of
1 of 6.44, 6.47, 6.48, 6.51, and
6.52; the distances between the atoms at the
position of
Cys/Ser/Thr (6.47) to the carboxyl oxygen at i
3 (6.44) and
i
4 (6.43) and the average for each group.
The Pro-kink can be described with bend angle, wobble angle, and face
shift (28). To assess the configuration across the Pro-kink rather than
only the configuration N-terminal to the Pro, we have defined the face
shift differently from Visiers et al. (28). We used the
angle between the projection of the average of the vectors connecting
the
-carbons of the (i
3) and (i
4) amino
acids with the origin in the y,z-plane
(A
34) and the projection of the average of the vectors
connecting the
-carbons of the (i+3) and (i+4)
amino acids with the origin in the y,z-plane, instead of the
angle between A
34 and the projection of the vector
connecting the proline
-carbon with origin in the y,z-plane in Ref. 28. The transformation of the coordinates was similar to Visiers et al. (28). The calculation was
implemented in a Perl script that automatically calls CHARMM to
calculate the helix axis and extract the results from the output.
The output simulation structures were clustered using
Macromodel/Xcluster. Representative structures and the largest clusters were selected for illustration and these were superimposed on the
backbone atoms of 6.49 to 6.60 (extracellular region).
 |
RESULTS |
Potential Conformations and Backbone Interactions of
Cys6.47--
Cysteine residues in an
-helical context
are restricted to the gauche+ (g+) and
trans (t) rotamer conformations (Table
I), because the gauche
(g
) configuration induces a steric clash between the
sulfur atom and the backbone carbonyl of the i
3 position (20). The rotamer distribution of these side chains in an
-helical context is quite similar in soluble and membrane proteins (Table I) and
is consistent with the theoretical free energy calculated for different
rotamers (29).
In the g+ rotamer, Cys6.47 can H-bond the
backbone carbonyl of the i
4 residue, and this is the most
common rotamer configuration for a Cys residue in an
-helix. In an
-helix, the cyclic side chain of proline prevents its H-bonding to
the i
4 backbone carbonyl and also induces steric clash,
thereby bending the helix. The resulting Pro-kink conformation also
prevents H-bonding of the i+1 backbone amide to the
i
3 backbone carbonyl (16, 30). Cys6.47 is
i
3 from Pro6.50, and in the t
rotamer, the backbone carbonyl of 6.47 can act as an H-bond acceptor
for its own side chain. Thus, Cys6.47 can adopt two
different rotamers, and each rotamer can interact with the TM6 backbone
differently, with the potential to induce different conformations of
the adjacent Pro-kink. Unlike Cys and Ser, which can populate the
t rotamer, the
-branched Thr does not exist in
t, because of steric clash between the side chain methyl and
the backbone carbonyls at i
3 and i
4. We
therefore mutated Cys-2856.47 to Thr to assess the effect
of eliminating the t rotamer at this position, and to Ser as
a control.
Pharmacological Characterization of Mutant Receptors--
The
affinity of the antagonist [3H]CGP-12177 was not
significantly different in the mutants (C2856.47T and
C2856.47S) and WT (Table II).
C2856.47T had a 5-fold higher affinity for the agonist
isoproterenol than did WT, whereas the affinity of
C2856.47S was reduced 2-fold (Table II). In intact cells,
the maximum level of [3H]CGP-12177 binding to
C2856.47T was ~20% that of WT, whereas that of
C2856.47S was ~50% of WT (data not shown). After
normalization of receptor number with the alkylating reagent
EEDQ, the mean and standard error values for the
EC50 of the agonist epinephrine in the accumulation of cAMP
were 6.0 ± 1.2 (n = 3), 9.4 ± 1.2 (n = 3), and 1.6 ± 0.43 nM
(n = 3) for WT, C2856.47S, and
C2856.47T, respectively (Fig.
1). Thus, the potency of epinephrine was increased ~4-fold in C2856.47T. A higher potency for
agonist activation and increased agonist affinity in competition
experiments are features commonly associated with CAMs (31).
View this table:
[in this window]
[in a new window]
|
Table II
Antagonist and agonist binding to WT 2AR and the mutants
Saturation and competition binding to membranes prepared from WT and
the mutants were performed as described under "Experimental
Procedures."
|
|

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 1.
Epinephrine dose-response curves of WT and
mutants. cAMP accumulation in the WT and mutant receptors was
measured at the indicated epinephrine concentrations. Based on a
determination of [3H]CGP-12177 binding, the
concentrations of the alkylating reagent EEDQ (60 µM for
WT and 13 µM for C2856.47S) equalized the number
of receptors on the cell surface in WT and C2856.47S to that of
C2856.47T. Nonlinear regression was carried out using the
mean normalized values of three experiments. EC50 values
were obtained by fitting the data to a one-site sigmoidal model. The
EC50 values were 6.0, 9.4, and 1.6 nM for WT,
C2856.47S, and C2856.47T, respectively.
|
|
The Increased Basal cAMP Accumulation of C2856.47T Can
Be Reduced by Inverse Agonist--
We measured cAMP accumulation after
attempting to equalize the number of receptors by inactivating WT and
C2856.47S by pretreatment with EEDQ. Under these
conditions, basal cAMP accumulation in C2856.47T was about
2-fold higher than in WT and 6-fold higher than in C2856.47S (Fig.
2A). In the presence of an
appropriate concentration of forskolin, which directly activates
adenylate cyclase, we still observe an effect of receptor activation on
cAMP accumulation because of the synergistic effects of forskolin and
G
s on adenylate cyclase. The increase in cAMP produced
by forskolin, however, raises "basal" levels to a level where our
assay is more sensitive. Therefore, we also examined the effects of the
mutations of 6.47 on cAMP accumulation in the presence of 10 µM forskolin. In the presence of forskolin the 2-fold
elevation in cAMP in C2856.47T relative to WT and 6-fold
relative to C2856.47S was also observed (Fig.
2B), consistent with the basal determinations reported
above. Most importantly, treatment with the inverse agonist timolol (1 µM) did not significantly affect cAMP accumulation in WT
or C2856.47S (Fig.
2).2 In contrast, the cAMP
accumulation in C2856.47T was significantly decreased to a
level similar to that of WT and C2856.47S in both the basal
and the forskolin background (Fig. 2).

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 2.
Basal cAMP accumulation in the WT and mutant
receptors. The cAMP accumulation was measured with (open
bars) or without (filled bars) the inverse agonist
timolol (1 µM). Panel A shows basal cAMP
values. Panel B shows basal cAMP values measured in the
presence of 10 µM forskolin. Mean ± S.E. are shown
(n = 3-4). Based on a determination of
[3H]CGP12177 binding, the concentrations of the
alkylating reagent EEDQ (35 µM for WT and 13 µM for C285S) equalized the number of receptors in
C2856.47S to that of C2856.47T, but the number
of WT receptors was only reduced to twice that of the other mutants
(data not shown).
|
|
Correlation between the
1 Rotamers of Cys6.47,
Trp6.48, and Phe6.52--
The side chain
conformations of Trp and Phe residues in an
-helical environment are
restricted to g+ or t conformations, given that
the g
rotamer gives rise to steric clashes with the helix
backbone (20). In the simulations, when Trp6.48 adopted the
t rotamer, Phe6.52 also adopted the t
rotamer, whereas when Trp6.48 adopted the g+
rotamer, Phe6.52 was found in both conformations. On the
other hand, when Phe6.52 adopted the g+ rotamer,
Trp6.48 also adopted the g+ rotamer, whereas
when Phe6.52 adopted the t rotamer,
Trp6.48 was found in both conformations. This pattern most
likely results from a steric clash between Trp6.48 in
t and Phe6.52 in g+ (Fig.
3A), which is dependent upon
their positioning within the Pro-kink. In contrast, this combination of
rotamer conformations is tolerated without clash in a standard
-helix in a number of known proteins (data not shown). The clash
between Trp6.48t and
Phe6.52g+ implies the following correlated
motions: if Trp6.48t
Phe6.52t and if Phe6.52g+
Trp6.48g+. Thus, as proposed by Visiers
et al. (17), these two aromatic residues act as a
toggle switch.

View larger version (61K):
[in this window]
[in a new window]
|
Fig. 3.
Three-dimensional molecular representations
of the rotamer toggle switch. A, a
three-dimensional molecular representation of the effect of local
rotamer conformation on the Pro-kink configuration. The representative
structures of
Cys6.47t/Trp6.48g+/Phe6.52g+
(green) and
Cys6.47g+/Trp6.48t/Phe6.52t
(red) were taken from the Conformational Memories
simulations. 200-300 structures from each cluster were superimposed on
the backbone of 6.49-6.60, and their backbone ribbons are shown. Side
chains of 6.47, 6.48, 6.50, and 6.52 are shown in stick
representation. B, left panel shows the
interaction the side chain of Cys6.47 in the t
rotamer with Trp6.48 in g+, representing the
putative inactive state, which lowers the reactivity of
Cys6.47 with MTSEA (see text). Right panel shows
the side chain of Cys6.47 in the g+ rotamer and
Trp6.48 in t, representing the putative active
state, with increased accessibility and reactivity of
Cys6.47. C, left panel shows the lack
of interaction between Trp6.48 in g+ with a
substituted Cys at 6.52 in the putative inactive state. Right
panel shows the interaction between Trp6.48 in
t and a substituted Cys at 6.52 in the putative active
state, thereby decreasing the accessibility and reactivity of
Cys6.52 (see text). The Cys6.47 sulfur is shown in
yellow.
|
|
In our initial conformational searches, we found that particular
starting conformation/rotamer positions significantly impacted upon the
final distribution of distinct conformations. For example, if we
started the conformational search from
Trp6.48t/Phe6.52t, >90%
of the resulting structures contain
Trp6.48t/Phe6.52t (data
not shown). This likely resulted from the favorable interaction between
the aromatic side chains, the propensity for aromatic residues to be in
t in
-helices (32), and the need for complex coordinated
changes of multiple side chains and/or backbone angles for movement of
these side chains. In contrast, if the search started from
Trp6.48g+/Phe6.52 g+, the
position of these two side chains in the resulting structures was
highly correlated, with either g+/g+ (59 and
79%) or t/t (34 and 9%), depending on the
rotamer at 6.47 (g+ or t, respectively; see below).
In an attempt to minimize the impact of the starting structure, we
started simulations with Trp6.48 in g+ and
Phe6.52 in t, thereby breaking the correlation
between the rotamers at these two positions. If we started from
Trp6.48g+/Phe6.52t, a
high percentage of the resulting structures leave the starting uncorrelated state and become correlated, either in
t/t or g+/g+ (Table
III). We analyzed the relationship in the
final structures between the 6.47 rotamer and the different rotamer
combinations of 6.48 and 6.52 (Table III). There was a clear
correlation between the rotamer position of Cys6.47 and the
resulting rotamer conformation of 6.48. Specifically, when
Cys6.47 was in g+, 73% of 6.48 moved from the
initial g+ to t. In contrast, when 6.47 was in
t, 87% of 6.48 remained in g+ (Table III).
Similarly, with Thr6.47 in g+ or g
,
73 and 67% of 6.48, respectively, moved from the initial g+
to t. With Ser6.47 in g+ or
g
, 61 and 68% of 6.48, respectively, moved from the initial g+ to t, whereas with Ser6.47
in t, 70% of 6.48 remained in g+. Because Thr
does not exist in t, it is likely, therefore, that in the
C2856.47T mutant the Trp6.48 is significantly
overrepresented in t compared with its rotamer distribution
with Cys or Ser at 6.47.
View this table:
[in this window]
[in a new window]
|
Table III
The correlation of 1 of Cys6.47, Trp6.48,
and Phe6.52
The ratios of different combination of rotamers of resulting structures
from the conformational search are shown according to the ending
rotamer of 6.48 and 6.52. The starting combination of 1 6.48/6.52
was g+/t (see text). The 1 of 6.47 was
restrained at g+, g , or t, as
indicated.
|
|
Modulation of the Pro-kink in TM6 by the
1 Rotamer of 6.47, 6.48, and 6.52--
The resulting simulation structures can be
clustered into two major groups based on the rotamer conformations
of 6.47, 6.48, and 6.52, one with
Cys6.47t/Trp6.48g+/Phe6.52g+
and the other with
Cys6.47g+/Trp6.48t/Phe6.52t.
These two clusters have significant differences in the parameters representing the global characteristics of the Pro-kink, which results
primarily from the significant alteration in the backbone torsion
angles of 6.47 and 6.48 (Table IV). Even
a small local change in backbone resulting from the different rotamer
combinations could have a large impact on the position of the
cytoplasmic end of TM6.
View this table:
[in this window]
[in a new window]
|
Table IV
Structural effects of different rotamer combinations of 6.47, 6.48, and 6.52
The values are the means from the ~200 representative structures of
Cys6.47 t/Trp6.48
g+/Phe6.52 g+ and Cys6.47
g+/Trp6.48 t/Phe6.52 t
shown in Fig. 3A.
|
|
Thr at 6.47 exists predominantly in the g+ rotamer, and it
does not exist in the t rotamer. Because the
Thr6.47 mutant shows an activated phenotype, the 6.47 g+ conformation seems to favor and/or mimic the active
state. In contrast, Ser, which can populate the t rotamer,
showed a distribution of states similar to that of WT. Thus, we
hypothesize that
Cys6.47t/Trp6.48g+/Phe6.52g+
represents the inactive conformation of the receptor and that Cys6.47g+/Trp6.48t/Phe6.52t
represents the active state (see "Discussion").
MTSEA Reaction Rate of F2906.52C in WT and CAM
Background--
Cys-2856.47 in
2AR is
responsible for the inhibitory effect of MTSEA on ligand binding in
several
2AR CAMs (6, 7, 14). We inferred that this
increased accessibility of Cys6.47 to MTSEA resulted from a
rotation and/or tilting of TM6 associated with receptor activation.
Although a substantial backbone movement of TM6 around the Pro-kink
might contribute to such a conformational rearrangement, it is also
possible that a local change in the relative orientations of
Cys6.47 and Trp6.48 may contribute to the
difference in the accessibility of Cys6.47 in the inactive
and active states. In the simulations we noted an interaction between
the side chain of Cys6.47 in t and that of
Trp6.48 in g+ (Fig. 3B). In the
putative inactive state, this interaction may impact on the dielectric
environment of Cys6.47, making it more hydrophobic and
likely decreasing the ionization and therefore the reactivity of the
thiol. Furthermore, the bulky Trp6.48 side chain may also
sterically block MTSEA from accessing Cys6.47. In the
putative active state, when Trp6.48 is in the t
position, the Trp side chain would be much farther from
Cys6.47, and therefore Cys6.47 would be more
reactive with MTSEA because of the removal of the factors described
above (Fig. 3B).
In considering ways to test this hypothesis, we noted that a Cys
residue at position 6.52 would be able to have a similar stabilizing
interaction with Trp6.48 in the t conformation
(Fig. 3C). Thus, the F2906.52C mutant would have
an activation-dependent MTSEA accessibility phenotype
opposite to that of WT Cys6.47. That is, in the active
state, Trp6.48 in t would be expected to
interact with Cys6.52, thereby decreasing its reactivity
with MTSEA. Thus, we predicted that F2906.52C would
react with MTSEA more rapidly in the WT background than in a CAM
background. To test this prediction, we made the mutants F2906.52C in WT and F2906.52C in a well
characterized CAM background that contains several mutations at the
cytoplasmic end of TM6 (31). The binding affinity of these mutants for
[3H]CGP12177 was significantly lower than that of WT
receptor (5.8 ± 0.19 nM, n = 4, and
1.4 ± 0.35 nM, n = 3, for
F2906.52C in WT and F2906.52C in CAM,
respectively). This is consistent with the known role of
Phe6.52 in ligand binding (reviewed in Ref. 1). Consistent
with the prediction stated above, we found that the rate of reaction of MTSEA with F2906.52C in WT (261 ± 54 M
1 s
1, n = 5)
was 5-fold faster than the rate of reaction with F2906.52C
in CAM (48 ± 6 M
1 s
1,
n = 4) (Fig. 4).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 4.
Rate of reaction of F6.52C
in the WT background (open circle) and
F6.52C in a CAM background (filled circle)
with MTSEA. Specific binding was assayed as described under
"Experimental Procedures" after a 2-min incubation with the
indicated concentration of MTSEA. The mean ± S.E. are shown
(n = 4 for WT-F2906.52C; n = 5 for CAM-C2856.47S/F2906.52C).
|
|
 |
DISCUSSION |
Interactions at the cytoplasmic ends of TM3 and TM6 constrain the
relative mobility of these segments in the inactive state of the
2AR and related rhodopsin-like receptors (14). Upon release of this "ionic lock" the mobility of TM6 and its position relative to TM3 may be modulated by the configuration of its Pro-kink. If, as we hypothesized, the rotamer position of 6.47 modulates the TM6
Pro-kink, then because the
-branched Thr does not populate the
t rotamer, C2856.47T should favor conformations
of the receptor driven by the g+ rotamer, and destabilize
those conformations driven by the t rotamer. Because Ser can
exist in the t rotamer with a roughly similar frequency as
Cys, C2856.47S would be expected to resemble WT receptor in
its activation properties.
We found that C2856.47T had multiple properties of a CAM:
it had a higher basal level of cAMP accumulation, it had a higher basal level of cAMP in the presence of forskolin, it had a lower
EC50 for agonist stimulation of adenylyl cyclase, basal and
forskolin-stimulated basal activity was reduced substantially by the
inverse agonist timolol, and it had higher affinity for agonist in
competition binding studies. Therefore, C2856.47T has the
classical characteristics of a CAM, in which a greater fraction of
receptor is present in the active state (31, 33). In contrast,
C2856.47S had properties similar to that of WT.
Conformational Memories revealed that the rotamer conformations at
positions 6.47, 6.48, and 6.52 around Pro6.50 are
correlated. A change of 6.48 from g+ (its conformation in the rhodopsin inactive state structure), to t, must be
accompanied by a corresponding change of 6.52 to t to avoid
steric clash (Fig. 3A). On the other hand, a change of
Phe6.52 from t to g+ must be
accompanied by a corresponding change of 6.48 to g+ to avoid
the same steric clash. Thus in the
2AR and related
rhodopsin-like receptors these two residues may act in concert as part
of a rotamer toggle switch that transduces agonist binding into an
altered conformation of TM6 (17). The aromatic stacking interactions
between Trp6.48 and Phe6.52 may stabilize the
g+/g+ and t/t rotamer configurations. These favorable interactions between 6.48 and 6.52 are facilitated by the
presence of the Pro-kink, which brings these two residues closer to
each other, altering the relationship between these two side chains
from what would be much less favorable interactions in a standard
-helix (data not shown).
We also found that the rotamer conformation of 6.47 was significantly
correlated with the rotamer of 6.48, making 6.47 a critical part
of the rotamer toggle switch. Specifically, 6.47 in g+ was associated with 6.48 in t, and 6.47 in t was
associated with 6.48 in g+ (Table III). We propose that the
impact of mutation of 6.47 to Thr on activation results from both
altered H-bonding as well as modulation by the 6.47 side chain of the
rotamer toggle switch. Thus, we propose that
Cys6.47g+/Trp6.48t/Phe6.52t
represents the active state and that
Cys6.47t/Trp6.48g+/Phe6.52g+
represents the inactive state. With Trp6.48 in t
in the active state, Phe6.52 must also be in t
to avoid steric clash. In contrast, as discussed above, with
Trp6.48 in g+ in the inactive state, although
there is an increased propensity for 6.52 to be in g+, 6.52 may also exist in t, suggesting the possibility of a
diversity of inactive states, with the rotamer positions of 6.47 and
6.48 being more critical to its phenotype.
This hypothesis is consistent with a number of experimental results in
rhodopsin. Movement of the side chain of Trp6.48 from
g+ to t upon activation is consistent with the
inference from UV absorption spectrometry in rhodopsin that the indole
side chain of Trp-2656.48 changes orientation during the
inactive to active conformational transition (34) as well as with data
suggesting that a single Trp tilts toward the membrane during
activation (35).
Although 6.52 is an alanine in rhodopsin, in the inactive rhodopsin
structure the
-ionone ring and carbon chain of retinal interact with
6.48 in g+ in a configuration very similar to that of the
interaction of 6.48 in g+ with Phe6.52 in
g+ in the
2AR (Fig.
5). Photoisomerization of retinal from cis to trans moves the
-ionone ring toward TM4
(36) and thus away from Trp6.48, whose enhanced freedom and
subsequent rearrangement is involved in the activation mechanism of
rhodopsin. The exquisite lack of constitutive activity of rhodopsin may
result from the inability of 6.48 to move to the t rotamer
when constrained by bound 11-cis-retinal. For GPCRs, such as
the
2AR, which are activated by diffusible ligands, a
ligand that stabilizes Trp6.48 in the g+
conformation would, therefore, behave as an inverse agonist. One such
mechanism of inverse agonism may involve forcing or stabilizing
Phe6.52 into the g+ rotamer conformation, which
would in turn force Trp6.48 into the g+
conformation, and thereby promote the inactive state. Conversely, an
agonist that stabilizes Phe6.52 in the t rotamer
conformation would free Trp6.48 to adopt the t
conformation, and thereby promote the active state.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 5.
Three-dimensional representation of the
similar orientations of
11-cis-retinal/Trp6.48 in rhodopsin
(panel A) and Phe6.52/Trp6.48
in 2AR (panel
B). The 1 of Phe6.52 and
Trp6.48 are in g+, representing the putative
inactive state.
|
|
FTIR difference spectroscopy has been used to study the role of
cysteine residues in the photoactivation of rhodopsin (37). At least
one cysteine sulfhydryl was inferred to be structurally active during
rhodopsin photoactivation and to form a stronger hydrogen bond in the
activated state. The transmembrane cysteines proposed as candidates are
Cys-1674.56, Cys-2225.57, and
Cys-2646.47. Movement of Cys6.47 into the
g+ rotamer and the associated formation of a strong H-bond
with the i-4 carbonyl could be responsible for the
spectroscopic observations. In the high-resolution structure of
rhodopsin, which represents the inactive state of the receptor (38),
the
1 of 6.48 is in g+ and the
1 of
Cys-2646.47 is in a nonstandard rotamer position between
g+ and t. The modification of
Cys-2646.47 by mercury may have affected its rotamer
position. It is also possible that the Cys6.47 side chain
may be dynamic, with its coordinates representing the average of its
g+ and t rotameric conformations.
Based on the proximity of the side chain of Cys6.47 in
t and Trp6.48 in g+ in the
2AR simulations, we propose the existence of an interaction between S
of Cys6.47 and the N
of
Trp6.48 (Fig. 3B). This configuration is
consistent with the favored orientation of interaction between Cys and
Trp in the Residue Contact Atlas (39). The sulfur-aromatic interaction
has been characterized as an intermediate interaction between a purely van der Waals interaction and a H-bond (40). In the inactive state of
rhodopsin, the side chain of Trp-2656.48 forms a H-bond
with another residue (34). In the bovine rhodopsin structure (15),
which represents the inactive state of receptor, Cys-2646.47 appears to be the only residue that could form
a H-bond-like interaction with the indole side chain of
Trp-2656.48. Receptor activation alters tertiary
interactions and weakens this H-bond (34). We propose that the
interaction between Cys6.47t and
Trp6.48g+ in the inactive state accounts for the
H-bond feature of Trp-2656.48 that is lost during the
activation process.
In our simulations of the
2AR,
Cys6.47 in t is positioned at an appropriate
distance to H-bond to its own backbone carbonyl, i
3 from
Pro6.50. H-bonding of the Cys6.47 side chain to
its own carbonyl may contribute to the altered
angles at 6.47 and
6.48, thereby altering the Pro-kink conformation (Table IV, Fig.
3A) and repositioning the cytoplasmic end of TM6 away from
TM3 upon activation. Therefore, Cys6.47, through the
interaction of its S
with the indole N
of Trp6.48 and
the H-bond of its side chain to its own carbonyl, may link the
conformation of the aromatic cluster with the conformation of the
Pro-kink, thereby playing a critical role in the mechanism of receptor activation.
This local network of interactions may underlie the observed
correlations between the rotamer conformations of Cys6.47
and Trp6.48. The conformational changes associated with
receptor activation must involve a change in interhelical interactions.
Interestingly, in the high-resolution structure of bovine rhodopsin,
there is a water molecule in the cavity surrounded by
Cys6.47, Tyr6.51, Pro6.50,
Pro7.38, Phe7.41, and Ala7.42 (38).
Okada et al. (38) have hypothesized that electrostatic interactions between TM6 and TM7 through this bound water may stabilize
the inactive state, and it is further possible that alterations of
these interactions may facilitate the movements associated with activation.
The activation process of rhodopsin has also been found to produce bulk
dielectric changes surrounding Trp (34). The proximity of the bulky
aromatic side chain of Trp might substantially decrease the
accessibility of Cys6.47 in the inactive state, both
by decreasing the local dielectric and decreasing the ionization of the
sulfhydryl as well as through direct steric block. This is consistent
with the observation from our laboratory that Cys6.47 is
unreactive with MTSEA in the inactive state (6). In the proposed active
state, Cys6.47 and Trp6.48 are substantially
further apart, consistent with the observed reactivity of
Cys6.47 with MTSEA in the CAM background (6, 7, 14). Based
on our simulations and our clustering of the simulated structures into
what we inferred to be inactive and active configurations, we
hypothesized that in the active state, with 6.48 in the t
rotamer, a cysteine substituted for 6.52 might be shielded from
reaction with MTSEA, much like Cys6.47 is in the inactive
state. We carried out this experiment and found that
F2906.52C was ~5-fold less reactive in the CAM background
than in the WT background (Figs. 3C and 4), consistent with
our predictions. This provides experimental support for the proposed
inactive and active configurations and for the existence of a rotamer
toggle switch. Thus, with Trp6.48 in the inactive state
(g+), Cys6.47 is less accessible and with 6.48 in the active state (t) Cys6.52 is less
accessible. In addition, these data are significant because they
demonstrate for the first time that in a CAM particular positions are
less reactive with MTSEA, thereby arguing against a simple model in
which the CAM is simply a less stable, more dynamic molecule.
It is important to note that our simulations are performed with an
isolated TM6 out of the context of the helical bundle and lipid. It is
clear that studying a helix in isolation ignores known constraining
interactions with other TMs, and is clearly inadequate to predict the
global configuration of TM6. For this reason, we think it wise not to
overinterpret the exact Pro-kink parameters generated by the
simulations, and rather to simply note the differences between the two
sets of rotamer combinations. Nonetheless, based on the consistency of
the results with our experimental findings and the literature, it
appears that the methodology can identify local conformations and
correlations based on steric clashes and/or local intrahelical
interactions, and mutations like those presented here can be designed
to test the validity of these hypotheses. In summary, both our
experimental and computational results are consistent with the
hypothesis that coordinated rotamer changes of 6.47, 6.48, and 6.52 appear to be associated with receptor activation. This rotamer toggle
switch may impact the
-helix backbone and may modulate the movement of TM6 about the Pro-kink during receptor activation. Because in
rhodopsin-like receptors Cys6.47, Trp6.48, and
Pro6.50 are highly conserved and 6.52 is conserved as a
bulky residue (except in rhodopsin as discussed above), it is likely
that the rotamer toggle switch and its modulation of the TM6 Pro-kink
are generally involved in GPCR activation.
 |
ACKNOWLEDGEMENTS |
We thank Hanne Hastrup for constructing
mutant receptors used in this study as well as for preliminary
experiments. We thank Qiang Wang for help with preliminary simulations.
We thank Sergio Hassan, Arthur Karlin, Ernest Mehler, Judy Norris,
Patricia Reggio, and Harel Weinstein for helpful discussion.
 |
FOOTNOTES |
*
This work was supported by National Institute of Mental
Health Grants MH57324 and MH54137, grants from the G. Harold & Leila Y. Mathers Charitable Trust, and the Lebovitz Trust (to J. A. J.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
Both authors contributed equally to this work.
¶¶
To whom correspondence should be addressed. Tel.:
212-305-7308; Fax: 212-305-5594; E-mail: jaj2@columbia.edu.
Published, JBC Papers in Press, August 6, 2002, DOI 10.1074/jbc.M206801200
2
Although the lack of effect of timolol on the
level of basal activity in WT and C2856.47S was not
surprising given their lack of substantial constitutive activity (see
Ref. 14), it is somewhat surprising that the basal activity in the
presence of timolol was higher in WT than in C2856.47S or
C2856.47T. This might conceivably relate in part to the
2-fold higher expression level of WT after EEDQ treatment and/or to
differences in cAMP levels in the different stable pools that were
independent of
2 receptor expression.
 |
ABBREVIATIONS |
The abbreviations used are:
GPCR, G-protein-coupled receptors;
TM, transmembrane;
2AR,
2 adrenergic receptor;
CAM, constitutively active
mutants;
EEDQ, N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline;
WT, wild
type;
H-bond, hydrogen bond;
MTSEA, methanethiosulfonate
ethylammonium.
 |
REFERENCES |
| 1.
|
Shi, L.,
and Javitch, J. A.
(2002)
Annu. Rev. Pharmacol. Toxicol.
42,
437-467[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Gether, U.
(2000)
Endocr. Rev.
21,
90-113[Abstract/Free Full Text]
|
| 3.
|
Farrens, D. L.,
Altenbach, C.,
Yang, K.,
Hubbell, W. L.,
and Khorana, H. G.
(1996)
Science
274,
768-770[Abstract/Free Full Text]
|
| 4.
|
Sheikh, S. P.,
Zvyaga, T. A.,
Lichtarge, O.,
Sakmar, T. P.,
and Bourne, H. R.
(1996)
Nature
383,
347-350[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Gether, U.,
Lin, S.,
Ghanouni, P.,
Ballesteros, J. A.,
Weinstein, H.,
and Kobilka, B. K.
(1997)
EMBO J.
16,
6737-6747[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Javitch, J. A., Fu, D.,
Liapakis, G.,
and Chen, J.
(1997)
J. Biol. Chem.
272,
18546-18549[Abstract/Free Full Text]
|
| 7.
|
Rasmussen, S. G.,
Jensen, A. D.,
Liapakis, G.,
Ghanouni, P.,
Javitch, J. A.,
and Gether, U.
(1999)
Mol. Pharmacol.
56,
175-184[Abstract/Free Full Text]
|
| 8.
|
Jensen, A. D.,
Guarnieri, F.,
Rasmussen, S. G.,
Asmar, F.,
Ballesteros, J. A.,
and Gether, U.
(2001)
J. Biol. Chem.
276,
9279-9290[Abstract/Free Full Text]
|
| 9.
|
Arnis, S.,
Fahmy, K.,
Hofmann, K. P.,
and Sakmar, T. P.
(1994)
J. Biol. Chem.
269,
23879-23881[Abstract/Free Full Text]
|
| 10.
|
Scheer, A.,
Fanelli, F.,
Costa, T., De,
Benedetti, P. G.,
and Cotecchia, S.
(1996)
EMBO J.
15,
3566-3578[Medline]
[Order article via Infotrieve]
|
| 11.
|
Cohen, G. B.,
Yang, T.,
Robinson, P. R.,
and Oprian, D. D.
(1993)
Biochemistry
32,
6111-6115[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Alewijnse, A. E.,
Timmerman, H.,
Jacobs, E. H.,
Smit, M. J.,
Roovers, E.,
Cotecchia, S.,
and Leurs, R.
(2000)
Mol. Pharmacol.
57,
890-898[Abstract/Free Full Text]
|
| 13.
|
Sheikh, S. P.,
Vilardarga, J. P.,
Baranski, T. J.,
Lichtarge, O.,
Iiri, T.,
Meng, E. C.,
Nissenson, R. A.,
and Bourne, H. R.
(1999)
J. Biol. Chem.
274,
17033-17041[Abstract/Free Full Text]
|
| 14.
|
Ballesteros, J. A.,
Jensen, A. D.,
Liapakis, G.,
Rasmussen, S. G.,
Shi, L.,
Gether, U.,
and Javitch, J. A.
(2001)
J. Biol. Chem.
276,
29171-29177[Abstract/Free Full Text]
|
| 15.
|
Palczewski, K.,
Kumasaka, T.,
Hori, T.,
Behnke, C. A.,
Motoshima, H.,
Fox, B. A., Le,
Trong, I.,
Teller, D. C.,
Okada, T.,
Stenkamp, R. E.,
Yamamoto, M.,
and Miyano, M.
(2000)
Science
289,
739-745[Abstract/Free Full Text]
|
| 16.
|
Sansom, M. S.,
and Weinstein, H.
(2000)
Trends Pharmacol. Sci.
21,
445-451[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Visiers, I.,
Ballesteros, J. A.,
and Weinstein, H.
(2002)
Methods Enzymol.
343,
329-371[Medline]
[Order article via Infotrieve]
|
| 18.
|
Ballesteros, J. A.,
Deupi, X.,
Olivella, M.,
Haaksma, E. E.,
and Pardo, L.
(2000)
Biophys. J.
79,
2754-2760[Abstract/Free Full Text]
|
| 19.
|
Gray, T. M.,
and Matthews, B. W.
(1984)
J. Mol. Biol.
175,
75-81[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
McGregor, M. J.,
Islam, S. A.,
and Sternberg, M. J.
(1987)
J. Mol. Biol.
198,
295-310[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Ballesteros, J.,
and Weinstein, H.
(1995)
Methods Neurosci.
25,
366-428
|
| 22.
|
Liapakis, G.,
Ballesteros, J. A.,
Papachristou, S.,
Chan, W. C.,
Chen, X.,
and Javitch, J. A.
(2000)
J. Biol. Chem.
275,
37779-37788[Abstract/Free Full Text]
|
| 23.
|
Staehelin, M.,
Simons, P.,
Jaeggi, K.,
and Wigger, N.
(1983)
J. Biol. Chem.
258,
3496-3502[Abstract/Free Full Text]
|
| 24.
|
Jayasinghe, S.,
Hristova, K.,
and White, S. H.
(2001)
Protein Sci.
10,
455-458[Abstract/Free Full Text]
|
| 25.
|
Word, J. M.,
Lovell, S. C.,
LaBean, T. H.,
Taylor, H. C.,
Zalis, M. E.,
Presley, B. K.,
Richardson, J. S.,
and Richardson, D. C.
(1999)
J. Mol. Biol.
285,
1711-1733[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Guarnieri, F.,
and Wilson, S. R.
(1995)
J. Comp. Chem.
16,
648-653[CrossRef]
|
| 27.
|
Brooks, B. R.,
Bruccoleri, R. E.,
Olafson, B. D.,
States, D. J.,
Swaminathan, S.,
and Karplus, M.
(1983)
J. Comp. Chem.
4,
187-217[CrossRef]
|
| 28.
|
Visiers, I.,
Braunheim, B. B.,
and Weinstein, H.
(2000)
Protein Eng.
13,
603-606[Abstract/Free Full Text]
|
| 29.
|
Stapley, B. J.,
and Doig, A. J.
(1997)
J. Mol. Biol.
272,
456-464[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Ballesteros, J. A.,
and Weinstein, H.
(1992)
Biophys. J.
62,
107-109[Abstract/Free Full Text]
|
| 31.
|
Samama, P.,
Cotecchia, S.,
Costa, T.,
and Lefkowitz, R. J.
(1993)
J. Biol. Chem.
268,
4625-4636[Abstract/Free Full Text]
|
| 32.
|
Lovell, S. C.,
Word, J. M.,
Richardson, J. S.,
and Richardson, D. C.
(2000)
Proteins
40,
389-408[CrossRef][Medline]
[Order article via Infotrieve] |